US20220168356A1 - Allografts containing viable cells and methods therof - Google Patents
Allografts containing viable cells and methods therof Download PDFInfo
- Publication number
- US20220168356A1 US20220168356A1 US17/672,983 US202217672983A US2022168356A1 US 20220168356 A1 US20220168356 A1 US 20220168356A1 US 202217672983 A US202217672983 A US 202217672983A US 2022168356 A1 US2022168356 A1 US 2022168356A1
- Authority
- US
- United States
- Prior art keywords
- particles
- cells
- allograft
- tissue
- native
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 46
- 241000124008 Mammalia Species 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 71
- 239000002245 particle Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 60
- 210000001519 tissue Anatomy 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 33
- 230000008439 repair process Effects 0.000 claims description 31
- 102000008186 Collagen Human genes 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 23
- 229920001436 collagen Polymers 0.000 claims description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims description 22
- 239000002577 cryoprotective agent Substances 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 210000000130 stem cell Anatomy 0.000 claims description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- 229920002674 hyaluronan Polymers 0.000 claims description 16
- 229960003160 hyaluronic acid Drugs 0.000 claims description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 15
- 239000002953 phosphate buffered saline Substances 0.000 claims description 15
- 230000017423 tissue regeneration Effects 0.000 claims description 9
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 8
- 102000016284 Aggrecans Human genes 0.000 claims description 8
- 108010067219 Aggrecans Proteins 0.000 claims description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 8
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 102000012422 Collagen Type I Human genes 0.000 claims description 5
- 108010022452 Collagen Type I Proteins 0.000 claims description 5
- 102000016611 Proteoglycans Human genes 0.000 claims description 5
- 108010067787 Proteoglycans Proteins 0.000 claims description 5
- 230000007547 defect Effects 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000012620 biological material Substances 0.000 abstract description 42
- 210000003954 umbilical cord Anatomy 0.000 abstract description 42
- 210000000845 cartilage Anatomy 0.000 abstract description 29
- 239000007943 implant Substances 0.000 abstract description 29
- 239000000306 component Substances 0.000 abstract description 24
- 230000029663 wound healing Effects 0.000 abstract description 4
- 239000003102 growth factor Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 12
- 230000035876 healing Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 10
- 210000002744 extracellular matrix Anatomy 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- -1 putty Substances 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 239000004696 Poly ether ether ketone Substances 0.000 description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 229920002530 polyetherether ketone Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000022159 cartilage development Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 230000002648 chondrogenic effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000002117 illicit drug Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009772 tissue formation Effects 0.000 description 3
- 230000008467 tissue growth Effects 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000005313 bioactive glass Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 208000018180 degenerative disc disease Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000000278 osteoconductive effect Effects 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000002138 osteoinductive effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010023509 Kyphosis Diseases 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- 206010049514 Traumatic fracture Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012213 gelatinous substance Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000004820 osteoconduction Effects 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3612—Cartilage, synovial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3654—Cartilage, e.g. meniscus
- A61L27/3658—Intervertebral discs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/38—Materials or treatment for tissue regeneration for reconstruction of the spine, vertebrae or intervertebral discs
Definitions
- the present invention relates generally to bone, cartilage, and tissue healing biomaterials, and in particular, allogenic biomaterials containing viable cells.
- the invention also relates to methods of making the materials and implants, for example, derived from intervertebral discs and/or umbilical cords, and methods of promoting bone, cartilage, or wound healing in a mammal by administering the biomaterial or implant to the mammal.
- the invention further relates to kits that include one or more of the biomaterials, implants, or components thereof.
- Bone, cartilage, or tissue grafting is a surgical procedure that replaces missing bone, cartilage, or tissue and/or repairs bone, cartilage, or tissue.
- Bone, cartilage, and tissue generally have the ability to regenerate well but may require a scaffold or other growth enhancers to do so effectively.
- Grafts may be allograft (e.g., cadaveric origin or live donors), autologous (e.g., bone or tissue harvested from the patient's own body), or synthetic. Bone, cartilage, and/or tissue grafts may be resorbed and replaced as the natural bone, cartilage, or tissue heals over time.
- successful biomaterials may promote chondrogenesis, the process by which cartilage is developed.
- successful biomaterials may include osteoconduction (guiding the reparative growth of the natural bone or tissue), osteoinduction (encouraging undifferentiated cells to become active osteoblasts), and/or osteogenesis (living bone cells in the graft material contributing to bone or tissue remodeling).
- successful biomaterials may include other suitable pathways or properties to enhance tissue formation and development.
- traditional grafts may exhibit certain advantages, traditional allograft may not exhibit the properties desired, may be difficult to obtain, or may not be in a shape or form suitable for implantation.
- allograft biomaterials described herein may be configured to promote tissue, bone, and/or cartilage healing and repair.
- the allograft compositions or implants prepared therefrom may be derived, for example, from intervertebral discs and/or umbilical cords.
- the allograft includes viable cells, for example, which were native to the intervertebral discs and/or umbilical cords that the allograft was derived from.
- the allografts may be particularly suitable for use in cartilage, bone, or other tissue healing or when living cells are needing during a surgical procedure.
- a composition for aiding tissue regeneration includes allograft particles derived from human intervertebral disc comprising native collagen, native proteoglycan, and native viable cells.
- the native viable cells may include one or more of chondrocytic cells, notochordal cells, nucleus pulposus stem/progenitor cells, fibrocytic cells, and combinations thereof.
- the native collagen may include collagen I, collagen II, or both.
- the allograft may be derived from the nucleus pulposus, the annulus fibrosus, or both of the components of the intervertebral disc.
- the particles may have a particle size, for example, ranging from about 250 microns to about 3 mm.
- the composition may further include a cryoprotectant, which may be decanted prior to use, a carrier solution, or other component.
- a cryoprotectant which may be decanted prior to use
- the carrier solution may include one or more of hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and polyethylene glycol (PEG).
- a method of preparing an implantable composition for aiding tissue regeneration may include obtaining intervertebral disc from a human subject; washing the intervertebral disc with a phosphate buffered saline solution containing antibiotics; and milling the intervertebral disc into particles to form the implantable composition.
- the method may further include one or more of the following steps: rinsing the particles, for example, with saline; combining the particles with a cryoprotectant to form a mixture, and freezing the mixture, for example, at a temperature of from ⁇ 80° C.
- HA hyaluronic acid
- collagen e.g., collagen, aggrecan, chondroitin sulfate
- PEG polyethylene glycol
- a composition for aiding tissue regeneration may include a patch derived from umbilical cord comprising native viable cells including native epithelial stem cells and native mesenchymal stem cells.
- the patch may include an upper layer of native Wharton's jelly and a lower layer of native epithelium.
- a method of preparing an implantable composition for aiding tissue regeneration may include obtaining umbilical cord from a human subject; separating and removing the veins and arteries from the umbilical cord; processing the umbilical cord into a patch to form the implantable composition.
- the method may further include one or more of the following steps: rinsing the umbilical cord, for example, with saline; milling the umbilical cord into particles; combining the particles with a cryoprotectant to form a mixture, and freezing the mixture, for example, at a temperature of from ⁇ 80° C.
- the umbilical cord to ⁇ 180° C.; thawing the mixture and decanting the cryoprotectant before use; treating the umbilical cord with an enzyme to decellularize part or all of the patch; and/or seeding the umbilical cord, for example, with exogenous mesenchymal stem cells isolated from bone or bone marrow aspirate.
- a method of promoting bone, disc, tissue, or wound healing in a mammal may include providing an allograft composition, for example, including allograft derived from intervertebral disc and/or umbilical cord; and administering the composition into a target repair site to facilitate repair or regeneration of tissue at the target repair site.
- the target repair site may be an injury or defect in the spine and the tissue being regenerated is bone or intervertebral disc.
- a kit includes one or more of the components, compositions, or implants described herein, retrieval kits, trays, syringes, or other components for combining and administering the biomaterial components.
- the kit may contain powder, putty, gel, strip, and/or extrudable versions of the compositions.
- the kit may contain compositions of the same or different types.
- the kit may include other components known in the art, including, but not limited to, carriers or scaffolds, cages (e.g., titanium and/or polyether ether ketone (PEEK) spacers), allograft spacers, cell culture media, phosphate buffered saline (PBS), a tissue culture substrate, retrieval tools, harvesting tools, implantation tools, or the like.
- cages e.g., titanium and/or polyether ether ketone (PEEK) spacers
- PEEK polyether ether ketone
- allograft spacers cell culture media
- PBS phosphate buffered saline
- retrieval tools e buffered saline
- harvesting tools implantation tools, or the like.
- FIG. 1 depicts a lateral view of an intervertebral disc between two adjacent vertebrae
- FIG. 2 depicts a superior view of the intervertebral disc shown in FIG. 1 ;
- FIG. 3 is a cross-sectional view of an umbilical cord
- FIG. 4 depicts a patch derived from umbilical cord according to one embodiment.
- the present invention relates generally to allograft biomaterial compositions and implants made therefrom that may be used in a variety of surgical procedures.
- the invention also relates to methods of making the compositions and implants, and methods of promoting bone, cartilage, tissue, or wound healing in a mammal by administering the biomaterial or implant to the mammal.
- the invention further relates to kits that include one or more of the biomaterials, implants, retrieval kits, tools and trays for mixing and combining ingredients, and other components thereof.
- BMP bone morphogenic protein
- Embodiments described herein may be generally directed to allograft biomaterial compositions, implants made therefrom, methods of making the same, and methods of using the same to promote healing of tissue, cartilage repair, and/or fusion of bone.
- compositions, biomaterials or implants may be discussed separately, it will be appreciated by one of ordinary skill in the art that the compositions or biomaterials described may be used in and of itself or may be used to create implants of different shapes, sizes, and orientations for a number of different clinical outcomes. Thus, the discussion of biomaterials or compositions may apply equally to the discussion on implants and vice versa.
- the allograft compositions or implants prepared therefrom may be derived, for example, from intervertebral discs and/or umbilical cords.
- the allograft includes viable cells.
- viable cells present in the allograft may be alive and capable of growth.
- the viable cells may be native to the intervertebral discs and/or umbilical cords that the allograft was derived from.
- native cells and/or other components of the allograft may include the original cells and tissues present in the intervertebral discs and/or umbilical cords when obtained from the donor.
- the native cells do not include exogenous, cultured, or expanded cells, although it is envisioned that such additional cells may be added to the allograft material, if desired.
- the allograft may include only native tissues and components present in the intervertebral discs and/or umbilical cords when obtained from the donor or may be combined with other tissues, natural materials, synthetics, or other components, for example, suitable to promote tissue regeneration and improve the handling and delivery of the product to the target site.
- the allograft biomaterial compositions may be chondrogenic. Chondrification or chondrogenesis is the process in which cartilage is formed.
- the cartilage may be formed from condensed mesenchyme tissue, which differentiates into chondrocytes, and secretes the molecules that form extracellular matrix for cartilage repair. Once damaged, cartilage may have limited natural repair capabilities. Because chondrocytes are bound in lacunae, they may not be able to naturally migrate to damaged areas.
- the allograft biomaterial compositions may contain chondrocytes, chondrogenic precursors, or other properties suitable for promoting chondrogenesis, thereby ultimately promoting cartilage or disc repair.
- the allograft biomaterial compositions may be osteogenic, osteoinductive, osteoconductive, and/or osteostimulative, which may be advantageous for tissue or bone healing and repair.
- the biomaterials may be osteoconductive when the material serves as a scaffold that provides surface area for new bone or tissue growth.
- the biomaterials may be osteoinductive if they stimulate osteoprogenitor cells or induce mesenchymal stem cells to differentiate into osteoblasts that then begin new bone or tissue formation.
- Biomaterials may be osteogenic if they contain cells (e.g., viable cells) that are capable of bone regeneration.
- the biomaterial may be osteostimulative if the material accelerates the bone or tissue formation process.
- the allograft biomaterial compositions may be configured to otherwise promote tissue healing.
- Tissue repair may be characterized by increased cell proliferation, capillary budding, and the synthesis of extracellular matrix (ECM) to fill in the damaged tissue.
- ECM extracellular matrix
- the allograft biomaterial compositions may contain cells, precursors, or other properties suitable for promoting tissue healing and repair.
- other tissues may include epithelial tissue, connective tissue, muscle tissue, or nerve tissue.
- the composition may also be “biocompatible” as that term refers to the ability (e.g., of a composition or material) to perform with an appropriate host response in a specific application, or at least to perform without having a toxic or otherwise deleterious effect on a biological system of the host, locally or systemically.
- biomaterial and/or implant or a portion thereof may be “biologically degradable” in that the material may be degraded by cellular absorption and/or hydrolytic degradation in a patient's body.
- the allograft biomaterial compositions may be configured to facilitate repair or regeneration of tissue, for example, bone, cartilage, or other tissue.
- the allograft biomaterial compositions may facilitate repair or regeneration of tissue at a target repair site.
- the target repair site can be, for example, a void, gap, or other defect, or a surgeon created opening in bone, cartilage, between bones, or other structure or tissue location in a body of a patient.
- the allograft biomaterial compositions may be configured to facilitate cartilage, bone, or other tissue growth at a target repair site.
- the allograft biomaterial compositions may be configured to be directly implanted or otherwise disposed at and in contact with the target repair site.
- the patient and target repair site may be in a human, mammal, or other organism.
- a composition for aiding tissue regeneration includes allograft derived from intervertebral disc.
- an intervertebral disc 20 and intervertebral foramen 14 lie between adjacent vertebrae 10 in the vertebral column.
- Each disc 20 forms a fibrocartilaginous joint (a symphysis), to allow slight movement of the vertebrae 10 , and acts as a ligament to hold the vertebrae 10 together.
- the intervertebral disc 20 contains two major components: the annulus fibrosus 22 and the nucleus pulposus 24 .
- the nucleus pulposus 24 is the central region.
- the nucleus pulposus 24 is a hydrated gelatinous structure responsible for distributing loads.
- the nucleus pulposus 24 is an avascular, immune privileged tissue with high collagen II and proteoglycan content.
- the nucleus pulposus 24 contains various cell types including chondrocytic cells, notochordal cells and nucleus pulposus stem/progenitor cells.
- Encircling the nucleus pulposus 24 the annulus fibrosus 22 confers ligament-like restraint properties.
- the outer lamellae of the annulus fibrosus 22 contain small diameter sensory nerve fibers, which contribute to mechanotransduction.
- the annulus fibrosus 22 receives a small vascular supply from encircling veins and capillary networks.
- the annulus fibrosus 22 has a high collagen I content and contains fibrocytic cells.
- the intervertebral disc 20 may be derived from healthy, cadaveric donor(s).
- the discs 20 may be derived from healthy human discs from the cervical, thoracic, and lumbar regions of the spine.
- the intervertebral disc 20 is preferably screened for various diseases, illicit drug use, and signs of degeneration.
- the intervertebral disc 20 is processed to obtain the resulting allograft.
- the intervertebral disc 20 is derived from a human subject, although it is envisioned that the disc may be derived from other vertebrate animals.
- the resulting allograft may comprise native collagen from the disc, native proteoglycan from the disc, and native viable cells from the disc.
- the native viable cells may include one or more of chondrocytic cells, notochordal cells, nucleus pulposus stem/progenitor cells, fibrocytic cells, and combinations thereof.
- the native collagen may include collagen I, collagen II, or both.
- the allograft may be derived from the nucleus pulposus, the annulus fibrosus, or both of the components of the intervertebral disc.
- the allograft may contain collagen II, proteoglycan, chondrocytic cells, notochordal cells and nucleus pulposus stem/progenitor cells.
- the allograft may contain collagen I and fibrocytic cells.
- the intervertebral disc may be processed to obtain the allograft.
- the discs may be processed to separate the disc from the vertebral bodies, and then rinsed, for example, in saline to remove any blood components.
- the disc or allograft may be rinsed in a phosphate buffered saline multiple times.
- the phosphate buffered saline may contain one or more antibiotics, such as penicillin-streptomycin.
- the disc is preferably minimally manipulated to maintain all or most of the native disc cells.
- the disc may be milled into particles, morselized, micronized, liquefied, or the native disc cells may be extracted therefrom.
- the intervertebral disc is milled into particles.
- the particles may be uniform or non-uniform in shape and size.
- the particles may have a particle size, for example, ranging from about 100 microns to about 5 mm, about 150 microns to about 4 mm, about 250 microns to about 3 mm, about 250 microns to about 1 mm, or about 250 microns to about 750 microns.
- the particles are of a sufficiently small size that they are able to be injected, for example, through a syringe into a patient's disc space using a minimally invasive technique.
- the allograft particles may be further rinsed in saline, for example, phosphate buffered saline multiple times (e.g., 2 or 3 times) to remove any remaining blood components or contaminants.
- Suitable carriers, scaffolds, or additives may include, but are not limited to, demineralized bone matrix (DBM) or other bone-derived components, ceramics including bioactive glasses or tricalcium phosphates, collagen including soluble and insoluble collagen, bone morphogenetic proteins (BMPs), phospholipids, carboxylmethylcellulose (CMC), glycerin, glycerol, polyethylene glycol (PEG), dextran, dextrose, hydrogels, poloxamers, polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), other copolymers of the same family, and combinations thereof.
- DBM demineralized bone matrix
- BMPs bone morphogenetic proteins
- CMC carboxylmethylcellulose
- PEG polyethylene glycol
- PEG polyethylene glycol
- dextran dextrose
- hydrogels poloxamers
- PLM polylactic acid
- PLA polylactic-co-glycolic acid
- biological agents may be added to the biomaterial or implant, such as bone growth factors such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin derived growth factor (IDGF), a keratinocyte derived growth factor (KDGF), or a fibroblast derived growth factor (FDGF), stem cells, and platelet rich plasma (PRP), to name a few.
- bone growth factors such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin derived growth factor (IDGF), a keratinocyte derived growth factor (KDGF), or a fibroblast derived growth factor (FDGF), stem cells, and platelet rich plasma (PRP), to name a few.
- PDGF platelet derived growth factor
- VEGF vascular endothelial growth factor
- IDGF insulin derived growth factor
- KDGF keratinocyte derived growth factor
- FDGF fibroblast derived growth factor
- stem cells such as platelet
- the allograft may be preserved.
- the allograft may be preserved with a cryoprotectant and frozen for later use.
- the cryoprotectant may include minimum essential medium, dimethyl sulfoxide (e.g., 10% DMSO), glycerol, polyethylene glycol (PEG), dextran, dextrose, or a combination thereof.
- the allograft may be mixed with the cryoprotectant and frozen at a temperature between ⁇ 80° C. and ⁇ 180° C., preferably at either ⁇ 80° C. or ⁇ 180° C. When ready to be implanted in a patient, the frozen mixture may be thawed and the cryoprotectant may be decanted prior to use.
- the allograft particles may be combined with a carrier solution.
- the carrier solution may include one or more of hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, polyethylene glycol (PEG), dextran, dextrose, or other suitable carriers.
- the carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF).
- TGF-B transforming growth factor
- GDF growth differentiation factor
- the final particle and carrier solution may be implanted in the patient.
- the allograft particles may be combined with the carrier solution before freezing or after decanting the cryoprotectant. For example, at the time of the surgical procedure, the particles may be thawed, the cryoprotectant decanted, and the allograft particles combined with the carrier solution.
- the native cells may be cultured.
- the particles may be rinsed in saline, for example, phosphate buffered saline multiple times (e.g., 2 or 3 times). After the rinse, the particles may be cultured in medium, for example, for up to 10 days.
- the medium may contain minimum essential medium or Dulbecco's Modified Eagle's Medium with or without the following supplements: dexamethasone, Penicillin-Streptomycin, ascorbic acid, bovine serum albumin (BSA), linoleic acid (LA), insulin, transferrin, selenous acid, proline, and growth factors (TGF-B and/or GDF). Supplements may increase cell count and maintain a nucleus pulposus-like phenotype.
- the particles with proliferated cells may be placed in cryoprotectant and frozen, for example, at ⁇ 80° C. or ⁇ 180° C.
- the allograft particles may be treated with an enzyme and/or cultured.
- the allograft particles may be treated with one or more enzymes, including protease and/or collagenase, for a suitable duration with periodic agitation.
- the supernatant may be filtered through a cell strainer, and the resulting cell suspension may be centrifuged.
- the enzyme solution may be aspirated, and the cell pellet may be resuspended in cell culture media.
- the cell solution may be plated in a tissue culture flask and cultured, for example, for up to 10 days. At the end of the culture period, the cells are detached using a dissociation agent and seeded with original extracellular matrix particles.
- the cells and extracellular matrix particles are placed in cryoprotectant, as described herein, and frozen. At the time of the surgical procedure, the cells and extracellular matrix particles may be thawed and implanted in the patient. Alternatively, the cells and extracellular matrix particles may be combined with a carrier solution as described herein. The resulting solution may be implanted in the patient.
- the resulting allografts may be particularly suitable for intervertebral disc repair. Due to minimal processing, the living cells remain viable in or on the allograft.
- the human allograft, derived from intervertebral disc may be used, for example, to treat degenerative disc disease (DDD) and may be a suitable replacement for spinal fusion surgery.
- DDD degenerative disc disease
- a composition for aiding tissue regeneration may include an allograft derived from umbilical cord.
- the umbilical cord is a conduit between the developing embryo or fetus and the placenta.
- the umbilical cord 30 contains one vein 32 , which carries oxygenated, nutrient-rich blood to the fetus, and two arteries 34 that carry deoxygenated, nutrient-depleted blood away.
- the umbilical cord 30 contains Wharton's jelly 36 , a gelatinous substance made largely from mucopolysaccharides which protects the blood vessels inside.
- the umbilical cord 30 is surrounded by cord lining or umbilical cord lining membrane 38 , which is the outermost layer of the umbilical cord 30 .
- the umbilical cord lining membrane 38 comprises two layers: the amniotic or epithelial layer 40 and the sub-amniotic or mesenchymal layer 42 .
- the umbilical cord lining membrane 38 is a rich source of two strains of stem cells: epithelial stem cells (from the epithelial layer 40 ) and mesenchymal stem cells (from the mesenchymal layer 42 ).
- the umbilical cord 30 In preparing the allograft, the umbilical cord 30 , with or without attached placentas, may be obtained from volunteer donors. In particular, donors may include mothers who have undergone an elective Caesarian procedure for childbirth.
- the umbilical cord 30 is preferably screened for various diseases, illicit drug use, and signs of degeneration.
- the umbilical cord 30 is processed to obtain the resulting allograft.
- the umbilical cord 30 is derived from a human subject, although it is envisioned that the cord may be derived from other mammals.
- the resulting allograft may comprise the native umbilical cord lining membrane, native viable cells including native epithelial stem cells and native mesenchymal stem cells, and/or native Wharton's jelly. Although specific tissues and cells are described here, it is understood that any of the other tissues and components known to be present in the native cord may be present in the resulting allograft.
- the umbilical cord may be processed to obtain the allograft.
- the veins and arteries may be removed and separated from the remainder of the umbilical cord.
- the remaining umbilical cord may comprise Wharton's jelly and amniotic epithelium.
- the umbilical cord product is preferably minimally manipulated such that any native viable cells, such as the native mesenchymal stem cells and native epithelial stem cells, remain in the final product.
- the layer may be processed into a patch or sheet suitable for use in bone, cartilage, and/or tissue healing or other medical applications.
- the patch may have a given length, width, and thickness.
- the patch may be square, rectangular, round, or of other suitable shape.
- the length may range from about 1 cm to about 8 cm.
- the width may range from about 1 cm to about 4 cm. When round, the diameter may range from about 10 mm-16 mm.
- the thickness would be determined by the natural umbilical cord as obtained from the mother.
- the resulting patch may include an upper layer of native Wharton's jelly and mesenchymal stem cells and a lower layer of native amniotic epithelium and epithelial stem cells.
- the patch may be preserved, dried, rehydrated, or otherwise stored prior to use.
- the patch may be applied to or otherwise integrated with another framework, structures, scaffold, or cage.
- the umbilical-derived patch or a portion thereof may be applied to the upper and lower contact surfaces of an intervertebral spacer or implant. Examples of such implants are disclosed in U.S. Publication No. 2017/0202678, which is incorporated by reference herein in its entirety for all purposes.
- the umbilical cord allograft may be further processed, for example, milled, morselized, liquefied, or combined with other ingredients (e.g., living cells, bone-based products, etc.) to obtain the resultant product.
- ingredients e.g., living cells, bone-based products, etc.
- the umbilical cord-derived allograft may be used alone, it is also envisioned that the allograft may combined with other components.
- one or more carriers, scaffold materials, or processing additives may be used with the allograft composition.
- Suitable carriers, scaffolds, or additives may include, but are not limited to, demineralized bone matrix (DBM) or other bone-derived components, ceramics including bioactive glasses or tricalcium phosphates, collagen including soluble and insoluble collagen, bone morphogenetic proteins (BMPs), phospholipids, carboxylmethylcellulose (CMC), glycerin, glycerol, polyethylene glycol (PEG), hydrogels, poloxamers, polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), other copolymers of the same family, and combinations thereof.
- DBM demineralized bone matrix
- ceramics including bioactive glasses or tricalcium phosphates
- collagen including soluble and insoluble collagen
- BMPs bone morphogenetic proteins
- CMC carboxylmethylcellulose
- glycerin glycerin
- glycerol polyethylene glycol
- PEG polyethylene glycol
- hydrogels poloxamers
- PLA polylactic acid
- biological agents may be added to the biomaterial or implant, such as bone growth factors such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin derived growth factor (IDGF), a keratinocyte derived growth factor (KDGF), or a fibroblast derived growth factor (FDGF), stem cells, and platelet rich plasma (PRP), to name a few.
- bone growth factors such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin derived growth factor (IDGF), a keratinocyte derived growth factor (KDGF), or a fibroblast derived growth factor (FDGF), stem cells, and platelet rich plasma (PRP), to name a few.
- PDGF platelet derived growth factor
- VEGF vascular endothelial growth factor
- IDGF insulin derived growth factor
- KDGF keratinocyte derived growth factor
- FDGF fibroblast derived growth factor
- stem cells such as platelet
- the human allograft derived from umbilical cord, may be used in a variety of surgical procedures. Due to minimal processing, living cells may remain viable in or on the allograft.
- the allograft may be suitable for use in bone, cartilage, and/or tissue healing or other medical applications where living cells are needed.
- the umbilical cord may be decellularized using enzyme digestion and used as a scaffold or membrane as is, or may be seeded with exogenous mesenchymal stem cells, for example, isolated from bone or bone marrow aspirate to promote bone regeneration.
- the allograft biomaterials described herein and/or implants formed therefrom are intended to be applied at a tissue, bone or cartilage repair site, e.g., one resulting from injury or defect.
- the implant can be utilized in a wide variety of orthopedic, periodontal, neurosurgical, oral and maxillofacial surgical procedures.
- the biomaterials may be suitable for repairs of the vertebral column including spinal fusion and internal fixation; tumor surgery, e.g., deficit filling; discectomy; laminectomy; scoliosis, lordosis and kyphosis treatments.
- Possible clinical applications may include e.g., the treatment of spinal disc degeneration or disease, traumatic, pathologic, or stress fractures, congenital defects or fractures, or operative defects in any bone or between bones of the body.
- compositions and implants may be configured for use at various target repair sites within a body of a patient to facilitate bone, cartilage, and/or tissue growth therein.
- the composition is configured for use at a target repair site in the patient's spine.
- the composition can facilitate chondrogenic repair of the intervertebral disc between adjacent vertebrae.
- the composition can facilitate growth of bone between the body of a first vertebra and the body of a second vertebra to achieve interbody fusion of the two vertebrae.
- the composition may be used in conjunction with one or more mechanical supports (e.g., a cage or frame, spacer, plate, a plurality of screws and/or rods, or the like).
- the composition can be configured to be implanted into or at a target repair site in or at a different cartilage, bone, tissue or other structures of the patient's body.
- treating and the phrases “treatment of a disease” and “treatment of a condition” refer to executing a protocol that may include the use of the compositions, devices and methods herein and/or administering one or more biomaterials to a patient (human, normal or otherwise, or other mammal), in an effort to alleviate signs or symptoms of the disease or condition. Alleviation can occur prior to signs or symptoms of the disease or condition appearing, as well as after their appearance. Thus, “treating” or “treatment” includes “preventing” or “prevention” of disease or undesirable condition. In addition, “treating” or “treatment” does not require complete alleviation of signs or symptoms and does not require a cure to the ailment.
- kits that include components for making the present biomaterials and implants, including for example, carriers or scaffolds, cages (e.g., titanium and/or polyether ether ketone (PEEK) spacers), allograft spacers, demineralized bone materials, cell culture media, phosphate buffered saline (PBS), a tissue culture substrate such as a flask, trypsin, or mixtures, bone graft harvesting tools, bone marrow aspirate retrieval tools, or the like. Additional components, instructions and/or other apparatus may also be included.
- cages e.g., titanium and/or polyether ether ketone (PEEK) spacers
- PEEK polyether ether ketone
- allograft spacers demineralized bone materials
- cell culture media phosphate buffered saline (PBS)
- PBS phosphate buffered saline
- tissue culture substrate such as a flask, trypsin, or mixtures
- intervertebral disc is screened for various diseases, illicit drug use, and signs of degeneration.
- soft tissues such as tendon, muscle, and fat
- the intervertebral disc is washed in a phosphate buffered saline solution containing antibiotics (1-2% Penicillin-Streptomycin) 2-3 times.
- the intervertebral disc is minimally manipulated such that any native viable cells remain in the final product.
- the allograft includes nucleus pulposus, annulus fibrosus, or a combination of both tissues.
- the tissue is milled to particles (250 micron-3 mm size).
- the disc particles are rinsed with 0.9% saline 2-3 times. After the rinse, the particles are treated in one of the following ways:
- the particles are rinsed in phosphate buffered saline 2-3 times.
- the particles are mixed with a cryoprotectant (minimum essential medium and 10% Dimethyl Sulfoxide) and frozen at either ⁇ 80° C. or ⁇ 180° C. Immediately prior to use, the mixture is thawed and the cryoprotectant decanted.
- a cryoprotectant minimum essential medium and 10% Dimethyl Sulfoxide
- the particles are rinsed in phosphate buffered saline 2-3 times. After the rinse, the particles are placed in cryoprotectant and frozen at either ⁇ 80° C. or ⁇ 180° C. At the time of the surgical procedure, the particles are thawed and combined with a carrier solution containing one or more of the following: hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and/or polyethylene glycol (PEG).
- HA hyaluronic acid
- the carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF).
- TGF-B transforming growth factor
- GDF growth differentiation factor
- the particles are rinsed in phosphate buffered saline 2-3 times. After the rinse, the particles are cultured in medium for up to 10 days.
- the medium may contain minimum essential medium or Dulbecco's Modified Eagle's Medium with or without the following supplements: dexamethasone, Penicillin-Streptomycin, ascorbic acid, bovine serum albumin (BSA), linoleic acid (LA), insulin, transferrin, selenous acid, proline, and growth factors (TGF-B and/or GDF). Supplements may increase cell count and maintain an NP-like phenotype.
- the particles with proliferated cells may be placed in a cryoprotectant and frozen at either ⁇ 80° C. or ⁇ 180° C.
- the particles are rinsed in phosphate buffered saline 2-3 times. After the rinse, the particles are cultured in medium for up to 10 days.
- the medium may contain minimum essential medium or Dulbecco's Modified Eagle's Medium with or without the following supplements: dexamethasone, Penicillin-Streptomycin, ascorbic acid, bovine serum albumin (BSA), linoleic acid (LA), insulin, transferrin, selenous acid, proline, and growth factors (TGF-B and/or GDF). Supplements may increase cell count and maintain an NP-like phenotype.
- the particles with proliferated cells may be placed in a cryoprotectant and frozen at either ⁇ 80° C. or ⁇ 180° C.
- the particles are thawed and may be optionally combined with a carrier solution containing one or more of the following: hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and/or polyethylene glycol (PEG).
- HA hyaluronic acid
- PEG polyethylene glycol
- the carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF).
- TGF-B transforming growth factor
- GDF growth differentiation factor
- the particles may be treated with protease (e.g., Pronase® 1 mg/ml-10 mg/ml) and/or collagenase (1 mg/ml-10 mg/ml) for a total of 1-4 hours at 37° C., with periodic agitation.
- protease e.g., Pronase® 1 mg/ml-10 mg/ml
- collagenase (1 mg/ml-10 mg/ml-10 mg/ml
- the supernatant is filtered through a 40 ⁇ m-100 ⁇ m cell strainer, and the resulting cell suspension is centrifuged at 300 rcf for 5-15 minutes.
- the protease solution is aspirated, and the cell pellet is resuspended in cell culture media.
- the cell solution is plated in a tissue culture flask and cultured for up to 10 days.
- the cells are detached using a dissociation agent and seeded with original extracellular matrix particles.
- the cells and extracellular matrix particles are placed in cryoprotectant and frozen at either ⁇ 80° C. or ⁇ 180° C.
- the cells and extracellular matrix particles are thawed and optionally combined with a carrier solution.
- the carrier solution may contain one or more of the following: hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and/or polyethylene glycol (PEG).
- the carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF).
- TGF-B transforming growth factor
- GDF growth differentiation factor
Abstract
Description
- This application is a continuation application of U.S. application Ser. No. 16/210,464, filed on Dec. 5, 2018 (published as U.S. Pat. Pub. No. 2019-0201451), which claims priority to U.S. Provisional Application No. 62/613,107, filed Jan. 3, 2018 (expired), all of which are incorporated by reference herein in their entireties for all purposes.
- The present invention relates generally to bone, cartilage, and tissue healing biomaterials, and in particular, allogenic biomaterials containing viable cells. The invention also relates to methods of making the materials and implants, for example, derived from intervertebral discs and/or umbilical cords, and methods of promoting bone, cartilage, or wound healing in a mammal by administering the biomaterial or implant to the mammal. The invention further relates to kits that include one or more of the biomaterials, implants, or components thereof.
- Bone, cartilage, or tissue grafting is a surgical procedure that replaces missing bone, cartilage, or tissue and/or repairs bone, cartilage, or tissue. Bone, cartilage, and tissue generally have the ability to regenerate well but may require a scaffold or other growth enhancers to do so effectively. Grafts may be allograft (e.g., cadaveric origin or live donors), autologous (e.g., bone or tissue harvested from the patient's own body), or synthetic. Bone, cartilage, and/or tissue grafts may be resorbed and replaced as the natural bone, cartilage, or tissue heals over time.
- For cartilage, successful biomaterials may promote chondrogenesis, the process by which cartilage is developed. For bone, successful biomaterials may include osteoconduction (guiding the reparative growth of the natural bone or tissue), osteoinduction (encouraging undifferentiated cells to become active osteoblasts), and/or osteogenesis (living bone cells in the graft material contributing to bone or tissue remodeling). For other tissues, successful biomaterials may include other suitable pathways or properties to enhance tissue formation and development. Although traditional grafts may exhibit certain advantages, traditional allograft may not exhibit the properties desired, may be difficult to obtain, or may not be in a shape or form suitable for implantation.
- To meet this and other needs, allograft biomaterials described herein may be configured to promote tissue, bone, and/or cartilage healing and repair. The allograft compositions or implants prepared therefrom may be derived, for example, from intervertebral discs and/or umbilical cords. In an exemplary embodiment, the allograft includes viable cells, for example, which were native to the intervertebral discs and/or umbilical cords that the allograft was derived from. The allografts may be particularly suitable for use in cartilage, bone, or other tissue healing or when living cells are needing during a surgical procedure.
- According to one embodiment, a composition for aiding tissue regeneration includes allograft particles derived from human intervertebral disc comprising native collagen, native proteoglycan, and native viable cells. The native viable cells may include one or more of chondrocytic cells, notochordal cells, nucleus pulposus stem/progenitor cells, fibrocytic cells, and combinations thereof. The native collagen may include collagen I, collagen II, or both. The allograft may be derived from the nucleus pulposus, the annulus fibrosus, or both of the components of the intervertebral disc. The particles may have a particle size, for example, ranging from about 250 microns to about 3 mm. The composition may further include a cryoprotectant, which may be decanted prior to use, a carrier solution, or other component. If present, the carrier solution may include one or more of hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and polyethylene glycol (PEG).
- According to another embodiment, a method of preparing an implantable composition for aiding tissue regeneration may include obtaining intervertebral disc from a human subject; washing the intervertebral disc with a phosphate buffered saline solution containing antibiotics; and milling the intervertebral disc into particles to form the implantable composition. The method may further include one or more of the following steps: rinsing the particles, for example, with saline; combining the particles with a cryoprotectant to form a mixture, and freezing the mixture, for example, at a temperature of from −80° C. to −180° C.; thawing the mixture and decanting the cryoprotectant before use; combining the particles with a carrier solution containing one or more of hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and polyethylene glycol (PEG); culturing the particles in a medium to obtain particles with proliferated cells; and/or treating the particles with an enzyme.
- According to another embodiment, a composition for aiding tissue regeneration may include a patch derived from umbilical cord comprising native viable cells including native epithelial stem cells and native mesenchymal stem cells. The patch may include an upper layer of native Wharton's jelly and a lower layer of native epithelium.
- According to another embodiment, a method of preparing an implantable composition for aiding tissue regeneration may include obtaining umbilical cord from a human subject; separating and removing the veins and arteries from the umbilical cord; processing the umbilical cord into a patch to form the implantable composition. The method may further include one or more of the following steps: rinsing the umbilical cord, for example, with saline; milling the umbilical cord into particles; combining the particles with a cryoprotectant to form a mixture, and freezing the mixture, for example, at a temperature of from −80° C. to −180° C.; thawing the mixture and decanting the cryoprotectant before use; treating the umbilical cord with an enzyme to decellularize part or all of the patch; and/or seeding the umbilical cord, for example, with exogenous mesenchymal stem cells isolated from bone or bone marrow aspirate.
- According to yet another embodiment, a method of promoting bone, disc, tissue, or wound healing in a mammal may include providing an allograft composition, for example, including allograft derived from intervertebral disc and/or umbilical cord; and administering the composition into a target repair site to facilitate repair or regeneration of tissue at the target repair site. The target repair site may be an injury or defect in the spine and the tissue being regenerated is bone or intervertebral disc.
- According to yet another embodiment, a kit includes one or more of the components, compositions, or implants described herein, retrieval kits, trays, syringes, or other components for combining and administering the biomaterial components. For example, the kit may contain powder, putty, gel, strip, and/or extrudable versions of the compositions. The kit may contain compositions of the same or different types. In addition, the kit may include other components known in the art, including, but not limited to, carriers or scaffolds, cages (e.g., titanium and/or polyether ether ketone (PEEK) spacers), allograft spacers, cell culture media, phosphate buffered saline (PBS), a tissue culture substrate, retrieval tools, harvesting tools, implantation tools, or the like.
- A more complete understanding of the present invention, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
-
FIG. 1 depicts a lateral view of an intervertebral disc between two adjacent vertebrae; -
FIG. 2 depicts a superior view of the intervertebral disc shown inFIG. 1 ; -
FIG. 3 is a cross-sectional view of an umbilical cord; and -
FIG. 4 depicts a patch derived from umbilical cord according to one embodiment. - The present invention relates generally to allograft biomaterial compositions and implants made therefrom that may be used in a variety of surgical procedures. The invention also relates to methods of making the compositions and implants, and methods of promoting bone, cartilage, tissue, or wound healing in a mammal by administering the biomaterial or implant to the mammal. The invention further relates to kits that include one or more of the biomaterials, implants, retrieval kits, tools and trays for mixing and combining ingredients, and other components thereof.
- Additional aspects, advantages and/or other features of example embodiments of the invention will become apparent in view of the following detailed description. It should be apparent to those skilled in the art that the described embodiments provided herein are merely exemplary and illustrative and not limiting. Numerous embodiments of modifications thereof are contemplated as falling within the scope of this disclosure and equivalents thereto.
- In describing example embodiments, specific terminology is employed for the sake of clarity. However, the embodiments are not intended to be limited to this specific terminology. Unless otherwise noted, technical terms are used according to conventional usage.
- As used herein, “a” or “an” may mean one or more. As used herein “another” may mean at least a second or more. As used herein, unless otherwise required by context, singular terms include pluralities and plural terms include the singular.
- As used herein and in the claims, the terms “comprising” and “including” are inclusive or open-ended and do not exclude additional unrecited elements, compositional components, or method steps. Accordingly, the terms “comprising” and “including” encompass the more restrictive terms “consisting essentially of” and “consisting of.”
- Unless specified otherwise, all values provided herein include up to and including the endpoints given, and the values of the constituents or components of the compositions are expressed in weight percent or % by weight of each ingredient in the composition.
- Each compound or name used herein may be discussed interchangeably with respect to its chemical formula, chemical name, abbreviation, acronym, etc. For example, BMP may be used interchangeably with bone morphogenic protein.
- Embodiments described herein may be generally directed to allograft biomaterial compositions, implants made therefrom, methods of making the same, and methods of using the same to promote healing of tissue, cartilage repair, and/or fusion of bone. Although compositions, biomaterials or implants may be discussed separately, it will be appreciated by one of ordinary skill in the art that the compositions or biomaterials described may be used in and of itself or may be used to create implants of different shapes, sizes, and orientations for a number of different clinical outcomes. Thus, the discussion of biomaterials or compositions may apply equally to the discussion on implants and vice versa.
- According to one embodiment, the allograft compositions or implants prepared therefrom may be derived, for example, from intervertebral discs and/or umbilical cords. In an exemplary embodiment, the allograft includes viable cells. In other words, viable cells present in the allograft may be alive and capable of growth. The viable cells may be native to the intervertebral discs and/or umbilical cords that the allograft was derived from. In other words, native cells and/or other components of the allograft may include the original cells and tissues present in the intervertebral discs and/or umbilical cords when obtained from the donor. The native cells do not include exogenous, cultured, or expanded cells, although it is envisioned that such additional cells may be added to the allograft material, if desired. Similarly, the allograft may include only native tissues and components present in the intervertebral discs and/or umbilical cords when obtained from the donor or may be combined with other tissues, natural materials, synthetics, or other components, for example, suitable to promote tissue regeneration and improve the handling and delivery of the product to the target site.
- When used for cartilage or disc repair, the allograft biomaterial compositions may be chondrogenic. Chondrification or chondrogenesis is the process in which cartilage is formed. The cartilage may be formed from condensed mesenchyme tissue, which differentiates into chondrocytes, and secretes the molecules that form extracellular matrix for cartilage repair. Once damaged, cartilage may have limited natural repair capabilities. Because chondrocytes are bound in lacunae, they may not be able to naturally migrate to damaged areas. Thus, the allograft biomaterial compositions may contain chondrocytes, chondrogenic precursors, or other properties suitable for promoting chondrogenesis, thereby ultimately promoting cartilage or disc repair.
- When used for bone healing, the allograft biomaterial compositions may be osteogenic, osteoinductive, osteoconductive, and/or osteostimulative, which may be advantageous for tissue or bone healing and repair. The biomaterials may be osteoconductive when the material serves as a scaffold that provides surface area for new bone or tissue growth. The biomaterials may be osteoinductive if they stimulate osteoprogenitor cells or induce mesenchymal stem cells to differentiate into osteoblasts that then begin new bone or tissue formation. Biomaterials may be osteogenic if they contain cells (e.g., viable cells) that are capable of bone regeneration. The biomaterial may be osteostimulative if the material accelerates the bone or tissue formation process.
- When used for other tissue healing or regeneration, the allograft biomaterial compositions may be configured to otherwise promote tissue healing. Tissue repair may be characterized by increased cell proliferation, capillary budding, and the synthesis of extracellular matrix (ECM) to fill in the damaged tissue. Thus, the allograft biomaterial compositions may contain cells, precursors, or other properties suitable for promoting tissue healing and repair. For example, other tissues may include epithelial tissue, connective tissue, muscle tissue, or nerve tissue.
- The composition may also be “biocompatible” as that term refers to the ability (e.g., of a composition or material) to perform with an appropriate host response in a specific application, or at least to perform without having a toxic or otherwise deleterious effect on a biological system of the host, locally or systemically. The biomaterial and/or implant or a portion thereof may be “biologically degradable” in that the material may be degraded by cellular absorption and/or hydrolytic degradation in a patient's body.
- According to one embodiment, the allograft biomaterial compositions may be configured to facilitate repair or regeneration of tissue, for example, bone, cartilage, or other tissue. In particular, the allograft biomaterial compositions may facilitate repair or regeneration of tissue at a target repair site. The target repair site can be, for example, a void, gap, or other defect, or a surgeon created opening in bone, cartilage, between bones, or other structure or tissue location in a body of a patient. The allograft biomaterial compositions may be configured to facilitate cartilage, bone, or other tissue growth at a target repair site. The allograft biomaterial compositions may be configured to be directly implanted or otherwise disposed at and in contact with the target repair site. The patient and target repair site may be in a human, mammal, or other organism.
- According to one embodiment, a composition for aiding tissue regeneration includes allograft derived from intervertebral disc. As best seen in
FIGS. 1 and 2 , anintervertebral disc 20 andintervertebral foramen 14 lie betweenadjacent vertebrae 10 in the vertebral column. Eachdisc 20 forms a fibrocartilaginous joint (a symphysis), to allow slight movement of thevertebrae 10, and acts as a ligament to hold thevertebrae 10 together. Theintervertebral disc 20 contains two major components: theannulus fibrosus 22 and thenucleus pulposus 24. Thenucleus pulposus 24 is the central region. Thenucleus pulposus 24 is a hydrated gelatinous structure responsible for distributing loads. Thenucleus pulposus 24 is an avascular, immune privileged tissue with high collagen II and proteoglycan content. The nucleus pulposus 24 contains various cell types including chondrocytic cells, notochordal cells and nucleus pulposus stem/progenitor cells. Encircling thenucleus pulposus 24, theannulus fibrosus 22 confers ligament-like restraint properties. The outer lamellae of theannulus fibrosus 22 contain small diameter sensory nerve fibers, which contribute to mechanotransduction. In addition to peripheral innervation, theannulus fibrosus 22 receives a small vascular supply from encircling veins and capillary networks. Theannulus fibrosus 22 has a high collagen I content and contains fibrocytic cells. - In preparing the allograft, the
intervertebral disc 20, with or without attachedvertebrae 10, may be derived from healthy, cadaveric donor(s). Thediscs 20 may be derived from healthy human discs from the cervical, thoracic, and lumbar regions of the spine. Theintervertebral disc 20 is preferably screened for various diseases, illicit drug use, and signs of degeneration. Theintervertebral disc 20 is processed to obtain the resulting allograft. Preferably, theintervertebral disc 20 is derived from a human subject, although it is envisioned that the disc may be derived from other vertebrate animals. - The resulting allograft may comprise native collagen from the disc, native proteoglycan from the disc, and native viable cells from the disc. The native viable cells may include one or more of chondrocytic cells, notochordal cells, nucleus pulposus stem/progenitor cells, fibrocytic cells, and combinations thereof. The native collagen may include collagen I, collagen II, or both. The allograft may be derived from the nucleus pulposus, the annulus fibrosus, or both of the components of the intervertebral disc. When the nucleus pulposus is utilized, the allograft may contain collagen II, proteoglycan, chondrocytic cells, notochordal cells and nucleus pulposus stem/progenitor cells. When the annulus fibrosus is utilized, the allograft may contain collagen I and fibrocytic cells. Although specific tissues and cells are described here, it is understood that any of the other tissues and components known to be present in the native intervertebral disc may be present in the resulting allograft.
- The intervertebral disc may be processed to obtain the allograft. For example, the discs may be processed to separate the disc from the vertebral bodies, and then rinsed, for example, in saline to remove any blood components. For example, the disc or allograft may be rinsed in a phosphate buffered saline multiple times. The phosphate buffered saline may contain one or more antibiotics, such as penicillin-streptomycin. The disc is preferably minimally manipulated to maintain all or most of the native disc cells.
- The disc may be milled into particles, morselized, micronized, liquefied, or the native disc cells may be extracted therefrom. In an exemplary embodiment, the intervertebral disc is milled into particles. The particles may be uniform or non-uniform in shape and size. The particles may have a particle size, for example, ranging from about 100 microns to about 5 mm, about 150 microns to about 4 mm, about 250 microns to about 3 mm, about 250 microns to about 1 mm, or about 250 microns to about 750 microns. In some embodiments, it may be preferred that the particles are of a sufficiently small size that they are able to be injected, for example, through a syringe into a patient's disc space using a minimally invasive technique. After milling, the allograft particles may be further rinsed in saline, for example, phosphate buffered saline multiple times (e.g., 2 or 3 times) to remove any remaining blood components or contaminants.
- Although it is envisioned that the disc-derived allograft may be used alone, it is also envisioned that the allograft may combined with other components. For example, one or more carriers, scaffold materials, or processing additives may be used with the allograft composition. Suitable carriers, scaffolds, or additives may include, but are not limited to, demineralized bone matrix (DBM) or other bone-derived components, ceramics including bioactive glasses or tricalcium phosphates, collagen including soluble and insoluble collagen, bone morphogenetic proteins (BMPs), phospholipids, carboxylmethylcellulose (CMC), glycerin, glycerol, polyethylene glycol (PEG), dextran, dextrose, hydrogels, poloxamers, polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), other copolymers of the same family, and combinations thereof.
- Additionally, biological agents may be added to the biomaterial or implant, such as bone growth factors such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin derived growth factor (IDGF), a keratinocyte derived growth factor (KDGF), or a fibroblast derived growth factor (FDGF), stem cells, and platelet rich plasma (PRP), to name a few. If desired, one or more active pharmaceutical ingredients or medicaments may be incorporated into the biomaterial or implant as well. Biological agents may be added in any suitable pharmaceutically acceptable and effective amounts known in the art.
- After processing, the allograft may be preserved. For example, the allograft may be preserved with a cryoprotectant and frozen for later use. The cryoprotectant may include minimum essential medium, dimethyl sulfoxide (e.g., 10% DMSO), glycerol, polyethylene glycol (PEG), dextran, dextrose, or a combination thereof. The allograft may be mixed with the cryoprotectant and frozen at a temperature between −80° C. and −180° C., preferably at either −80° C. or −180° C. When ready to be implanted in a patient, the frozen mixture may be thawed and the cryoprotectant may be decanted prior to use.
- In another exemplary embodiment, the allograft particles may be combined with a carrier solution. If present, the carrier solution may include one or more of hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, polyethylene glycol (PEG), dextran, dextrose, or other suitable carriers. The carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF). The final particle and carrier solution may be implanted in the patient. The allograft particles may be combined with the carrier solution before freezing or after decanting the cryoprotectant. For example, at the time of the surgical procedure, the particles may be thawed, the cryoprotectant decanted, and the allograft particles combined with the carrier solution.
- In another embodiment, the native cells may be cultured. The particles may be rinsed in saline, for example, phosphate buffered saline multiple times (e.g., 2 or 3 times). After the rinse, the particles may be cultured in medium, for example, for up to 10 days. The medium may contain minimum essential medium or Dulbecco's Modified Eagle's Medium with or without the following supplements: dexamethasone, Penicillin-Streptomycin, ascorbic acid, bovine serum albumin (BSA), linoleic acid (LA), insulin, transferrin, selenous acid, proline, and growth factors (TGF-B and/or GDF). Supplements may increase cell count and maintain a nucleus pulposus-like phenotype. At the end of the culture period, the particles with proliferated cells may be placed in cryoprotectant and frozen, for example, at −80° C. or −180° C.
- According to another embodiment, the allograft particles may be treated with an enzyme and/or cultured. For example, the allograft particles may be treated with one or more enzymes, including protease and/or collagenase, for a suitable duration with periodic agitation. The supernatant may be filtered through a cell strainer, and the resulting cell suspension may be centrifuged. The enzyme solution may be aspirated, and the cell pellet may be resuspended in cell culture media. The cell solution may be plated in a tissue culture flask and cultured, for example, for up to 10 days. At the end of the culture period, the cells are detached using a dissociation agent and seeded with original extracellular matrix particles. The cells and extracellular matrix particles are placed in cryoprotectant, as described herein, and frozen. At the time of the surgical procedure, the cells and extracellular matrix particles may be thawed and implanted in the patient. Alternatively, the cells and extracellular matrix particles may be combined with a carrier solution as described herein. The resulting solution may be implanted in the patient.
- The resulting allografts may be particularly suitable for intervertebral disc repair. Due to minimal processing, the living cells remain viable in or on the allograft. The human allograft, derived from intervertebral disc, may be used, for example, to treat degenerative disc disease (DDD) and may be a suitable replacement for spinal fusion surgery.
- According to another embodiment, a composition for aiding tissue regeneration may include an allograft derived from umbilical cord. The umbilical cord is a conduit between the developing embryo or fetus and the placenta. As best seen in
FIGS. 3 and 4 , theumbilical cord 30 contains onevein 32, which carries oxygenated, nutrient-rich blood to the fetus, and twoarteries 34 that carry deoxygenated, nutrient-depleted blood away. Theumbilical cord 30 contains Wharton'sjelly 36, a gelatinous substance made largely from mucopolysaccharides which protects the blood vessels inside. Theumbilical cord 30 is surrounded by cord lining or umbilicalcord lining membrane 38, which is the outermost layer of theumbilical cord 30. The umbilicalcord lining membrane 38 comprises two layers: the amniotic orepithelial layer 40 and the sub-amniotic ormesenchymal layer 42. The umbilicalcord lining membrane 38 is a rich source of two strains of stem cells: epithelial stem cells (from the epithelial layer 40) and mesenchymal stem cells (from the mesenchymal layer 42). - In preparing the allograft, the
umbilical cord 30, with or without attached placentas, may be obtained from volunteer donors. In particular, donors may include mothers who have undergone an elective Caesarian procedure for childbirth. Theumbilical cord 30 is preferably screened for various diseases, illicit drug use, and signs of degeneration. Theumbilical cord 30 is processed to obtain the resulting allograft. Preferably, theumbilical cord 30 is derived from a human subject, although it is envisioned that the cord may be derived from other mammals. - The resulting allograft may comprise the native umbilical cord lining membrane, native viable cells including native epithelial stem cells and native mesenchymal stem cells, and/or native Wharton's jelly. Although specific tissues and cells are described here, it is understood that any of the other tissues and components known to be present in the native cord may be present in the resulting allograft.
- The umbilical cord may be processed to obtain the allograft. The veins and arteries may be removed and separated from the remainder of the umbilical cord. The remaining umbilical cord may comprise Wharton's jelly and amniotic epithelium. The umbilical cord product is preferably minimally manipulated such that any native viable cells, such as the native mesenchymal stem cells and native epithelial stem cells, remain in the final product. The layer may be processed into a patch or sheet suitable for use in bone, cartilage, and/or tissue healing or other medical applications. For example, the patch may have a given length, width, and thickness. The patch may be square, rectangular, round, or of other suitable shape. The length may range from about 1 cm to about 8 cm. The width may range from about 1 cm to about 4 cm. When round, the diameter may range from about 10 mm-16 mm. The thickness would be determined by the natural umbilical cord as obtained from the mother. The resulting patch may include an upper layer of native Wharton's jelly and mesenchymal stem cells and a lower layer of native amniotic epithelium and epithelial stem cells. The patch may be preserved, dried, rehydrated, or otherwise stored prior to use.
- The patch may be applied to or otherwise integrated with another framework, structures, scaffold, or cage. For example, the umbilical-derived patch or a portion thereof may be applied to the upper and lower contact surfaces of an intervertebral spacer or implant. Examples of such implants are disclosed in U.S. Publication No. 2017/0202678, which is incorporated by reference herein in its entirety for all purposes.
- In the alternative, if a patch or sheet is not desired, the umbilical cord allograft may be further processed, for example, milled, morselized, liquefied, or combined with other ingredients (e.g., living cells, bone-based products, etc.) to obtain the resultant product.
- Although it is envisioned that the umbilical cord-derived allograft may be used alone, it is also envisioned that the allograft may combined with other components. For example, one or more carriers, scaffold materials, or processing additives may be used with the allograft composition. Suitable carriers, scaffolds, or additives may include, but are not limited to, demineralized bone matrix (DBM) or other bone-derived components, ceramics including bioactive glasses or tricalcium phosphates, collagen including soluble and insoluble collagen, bone morphogenetic proteins (BMPs), phospholipids, carboxylmethylcellulose (CMC), glycerin, glycerol, polyethylene glycol (PEG), hydrogels, poloxamers, polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), other copolymers of the same family, and combinations thereof.
- Additionally, biological agents may be added to the biomaterial or implant, such as bone growth factors such as platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin derived growth factor (IDGF), a keratinocyte derived growth factor (KDGF), or a fibroblast derived growth factor (FDGF), stem cells, and platelet rich plasma (PRP), to name a few. If desired, one or more active pharmaceutical ingredients or medicaments may be incorporated into the biomaterial or implant as well. Biological agents may be added in any suitable pharmaceutically acceptable and effective amounts known in the art.
- The human allograft, derived from umbilical cord, may be used in a variety of surgical procedures. Due to minimal processing, living cells may remain viable in or on the allograft. The allograft may be suitable for use in bone, cartilage, and/or tissue healing or other medical applications where living cells are needed.
- In yet another embodiment, the umbilical cord may be decellularized using enzyme digestion and used as a scaffold or membrane as is, or may be seeded with exogenous mesenchymal stem cells, for example, isolated from bone or bone marrow aspirate to promote bone regeneration.
- The allograft biomaterials described herein and/or implants formed therefrom are intended to be applied at a tissue, bone or cartilage repair site, e.g., one resulting from injury or defect. The implant can be utilized in a wide variety of orthopedic, periodontal, neurosurgical, oral and maxillofacial surgical procedures. In particular, the biomaterials may be suitable for repairs of the vertebral column including spinal fusion and internal fixation; tumor surgery, e.g., deficit filling; discectomy; laminectomy; scoliosis, lordosis and kyphosis treatments. Possible clinical applications may include e.g., the treatment of spinal disc degeneration or disease, traumatic, pathologic, or stress fractures, congenital defects or fractures, or operative defects in any bone or between bones of the body.
- The compositions and implants may be configured for use at various target repair sites within a body of a patient to facilitate bone, cartilage, and/or tissue growth therein. In some embodiments, the composition is configured for use at a target repair site in the patient's spine. For example, the composition can facilitate chondrogenic repair of the intervertebral disc between adjacent vertebrae. In another example, the composition can facilitate growth of bone between the body of a first vertebra and the body of a second vertebra to achieve interbody fusion of the two vertebrae. In a spinal fusion procedure, the composition may be used in conjunction with one or more mechanical supports (e.g., a cage or frame, spacer, plate, a plurality of screws and/or rods, or the like). Although the spine is described, the composition can be configured to be implanted into or at a target repair site in or at a different cartilage, bone, tissue or other structures of the patient's body.
- The term “treating” and the phrases “treatment of a disease” and “treatment of a condition” refer to executing a protocol that may include the use of the compositions, devices and methods herein and/or administering one or more biomaterials to a patient (human, normal or otherwise, or other mammal), in an effort to alleviate signs or symptoms of the disease or condition. Alleviation can occur prior to signs or symptoms of the disease or condition appearing, as well as after their appearance. Thus, “treating” or “treatment” includes “preventing” or “prevention” of disease or undesirable condition. In addition, “treating” or “treatment” does not require complete alleviation of signs or symptoms and does not require a cure to the ailment.
- Further example embodiments are directed to kits that include components for making the present biomaterials and implants, including for example, carriers or scaffolds, cages (e.g., titanium and/or polyether ether ketone (PEEK) spacers), allograft spacers, demineralized bone materials, cell culture media, phosphate buffered saline (PBS), a tissue culture substrate such as a flask, trypsin, or mixtures, bone graft harvesting tools, bone marrow aspirate retrieval tools, or the like. Additional components, instructions and/or other apparatus may also be included.
- The following examples are provided to further illustrate various non-limiting embodiments and techniques. It should be understood, however, that these examples are meant to be illustrative and do not limit the scope of the claims. As would be apparent to skilled artisans, many variations and modifications are intended to be encompassed within the spirit and scope of the invention.
- In each of the examples described below intervertebral disc is screened for various diseases, illicit drug use, and signs of degeneration. Surrounding soft tissues, such as tendon, muscle, and fat, are removed from the spine, and the intervertebral disc (without endplates) is dissected from the vertebrae. The intervertebral disc is washed in a phosphate buffered saline solution containing antibiotics (1-2% Penicillin-Streptomycin) 2-3 times. The intervertebral disc is minimally manipulated such that any native viable cells remain in the final product. The allograft includes nucleus pulposus, annulus fibrosus, or a combination of both tissues. The tissue is milled to particles (250 micron-3 mm size). The disc particles are rinsed with 0.9% saline 2-3 times. After the rinse, the particles are treated in one of the following ways:
- The particles are rinsed in phosphate buffered saline 2-3 times. The particles are mixed with a cryoprotectant (minimum essential medium and 10% Dimethyl Sulfoxide) and frozen at either −80° C. or −180° C. Immediately prior to use, the mixture is thawed and the cryoprotectant decanted.
- The particles are rinsed in phosphate buffered saline 2-3 times. After the rinse, the particles are placed in cryoprotectant and frozen at either −80° C. or −180° C. At the time of the surgical procedure, the particles are thawed and combined with a carrier solution containing one or more of the following: hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and/or polyethylene glycol (PEG). The carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF). The final particle and carrier solution are then implanted in the patient.
- The particles are rinsed in phosphate buffered saline 2-3 times. After the rinse, the particles are cultured in medium for up to 10 days. The medium may contain minimum essential medium or Dulbecco's Modified Eagle's Medium with or without the following supplements: dexamethasone, Penicillin-Streptomycin, ascorbic acid, bovine serum albumin (BSA), linoleic acid (LA), insulin, transferrin, selenous acid, proline, and growth factors (TGF-B and/or GDF). Supplements may increase cell count and maintain an NP-like phenotype. At the end of the culture period, the particles with proliferated cells may be placed in a cryoprotectant and frozen at either −80° C. or −180° C.
- The particles are rinsed in phosphate buffered saline 2-3 times. After the rinse, the particles are cultured in medium for up to 10 days. The medium may contain minimum essential medium or Dulbecco's Modified Eagle's Medium with or without the following supplements: dexamethasone, Penicillin-Streptomycin, ascorbic acid, bovine serum albumin (BSA), linoleic acid (LA), insulin, transferrin, selenous acid, proline, and growth factors (TGF-B and/or GDF). Supplements may increase cell count and maintain an NP-like phenotype. At the end of the culture period, the particles with proliferated cells may be placed in a cryoprotectant and frozen at either −80° C. or −180° C.
- At the time of the surgical procedure, the particles are thawed and may be optionally combined with a carrier solution containing one or more of the following: hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and/or polyethylene glycol (PEG). The carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF). The final particle and carrier solution are then implanted in the patient.
- The particles may be treated with protease (e.g., Pronase® 1 mg/ml-10 mg/ml) and/or collagenase (1 mg/ml-10 mg/ml) for a total of 1-4 hours at 37° C., with periodic agitation. The supernatant is filtered through a 40 μm-100 μm cell strainer, and the resulting cell suspension is centrifuged at 300 rcf for 5-15 minutes. The protease solution is aspirated, and the cell pellet is resuspended in cell culture media. The cell solution is plated in a tissue culture flask and cultured for up to 10 days. At the end of the culture period, the cells are detached using a dissociation agent and seeded with original extracellular matrix particles. The cells and extracellular matrix particles are placed in cryoprotectant and frozen at either −80° C. or −180° C. At the time of the surgical procedure, the cells and extracellular matrix particles are thawed and optionally combined with a carrier solution. The carrier solution may contain one or more of the following: hyaluronic acid (HA), collagen, aggrecan, chondroitin sulfate, and/or polyethylene glycol (PEG). The carrier solution may also contain growth factors, such as transforming growth factor (TGF-B) and/or growth differentiation factor (GDF). The resulting solution is implanted in the patient.
- Although the invention has been described in example embodiments, those skilled in the art will appreciate that various modifications may be made without departing from the spirit and scope of the invention. It is therefore to be understood that the inventions herein may be practiced other than as specifically described. Thus, the present embodiments should be considered in all respects as illustrative and not restrictive. Accordingly, it is intended that such changes and modifications fall within the scope of the present invention as defined by the claims appended hereto.
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/672,983 US20220168356A1 (en) | 2018-01-03 | 2022-02-16 | Allografts containing viable cells and methods therof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862613107P | 2018-01-03 | 2018-01-03 | |
US16/210,464 US11285177B2 (en) | 2018-01-03 | 2018-12-05 | Allografts containing viable cells and methods thereof |
US17/672,983 US20220168356A1 (en) | 2018-01-03 | 2022-02-16 | Allografts containing viable cells and methods therof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/210,464 Continuation US11285177B2 (en) | 2018-01-03 | 2018-12-05 | Allografts containing viable cells and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220168356A1 true US20220168356A1 (en) | 2022-06-02 |
Family
ID=67057884
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/210,464 Active US11285177B2 (en) | 2018-01-03 | 2018-12-05 | Allografts containing viable cells and methods thereof |
US17/672,983 Pending US20220168356A1 (en) | 2018-01-03 | 2022-02-16 | Allografts containing viable cells and methods therof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/210,464 Active US11285177B2 (en) | 2018-01-03 | 2018-12-05 | Allografts containing viable cells and methods thereof |
Country Status (1)
Country | Link |
---|---|
US (2) | US11285177B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11285177B2 (en) * | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
US11090412B2 (en) | 2018-12-21 | 2021-08-17 | Zavation Medical Products Llc | Bone repair composition and kit |
WO2024030479A1 (en) * | 2022-08-02 | 2024-02-08 | Lifenet Health | Birth tissue for surgical repairs |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067480A1 (en) * | 2002-10-04 | 2004-04-08 | Organ Recovery Systems, Inc. | Method for treatment of cellular materials with sugars prior to preservation |
US20080014179A1 (en) * | 2006-07-11 | 2008-01-17 | Ferree Bret A | Tissue transplantation compositions and methods |
US9655929B2 (en) * | 2014-07-17 | 2017-05-23 | Vivex Biomedical, Inc. | Spinal disc regenerative composition and method of manufacture and use |
US11285177B2 (en) * | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5155034A (en) | 1988-06-30 | 1992-10-13 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Three-dimensional cell to tissue assembly process |
US5496722A (en) | 1988-06-30 | 1996-03-05 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method for producing non-neoplastic, three dimensional, mammalian tissue and cell aggregates under microgravity culture conditions and the products produced therefrom |
FR2654625B1 (en) | 1989-11-22 | 1992-02-21 | Transphyto Sa | PROCESS FOR MANUFACTURING A MATERIAL FOR OSTEOPLASTY FROM A NATURAL BONE TISSUE AND MATERIAL OBTAINED BY THIS PROCESS. |
US5256418A (en) | 1990-04-06 | 1993-10-26 | Organogenesis, Inc. | Collagen constructs |
RU2071737C1 (en) | 1993-07-13 | 1997-01-20 | Московский областной научно-исследовательский клинический институт | Method for stimulating bone tissue repair |
US20020095218A1 (en) | 1996-03-12 | 2002-07-18 | Carr Robert M. | Tissue repair fabric |
US5964807A (en) | 1996-08-08 | 1999-10-12 | Trustees Of The University Of Pennsylvania | Compositions and methods for intervertebral disc reformation |
US6152142A (en) | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
US20020098222A1 (en) * | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
US6080579A (en) | 1997-11-26 | 2000-06-27 | Charlotte-Mecklenburg Hospital Authority | Method for producing human intervertebral disc cells |
US7101545B1 (en) | 1997-11-26 | 2006-09-05 | Charlotte-Mecklenburg Hospital Authority | Method for using human intervertebral disc cells |
US7294144B1 (en) | 1998-08-10 | 2007-11-13 | Schneider James R | Preserved implantable vessel derived from a human umbilical cord or placenta |
US6696073B2 (en) | 1999-02-23 | 2004-02-24 | Osteotech, Inc. | Shaped load-bearing osteoimplant and methods of making same |
US6340369B1 (en) | 1999-08-13 | 2002-01-22 | Bret A. Ferree | Treating degenerative disc disease with harvested disc cells and analogues of the extracellular matrix |
US6344058B1 (en) | 1999-08-13 | 2002-02-05 | Bret A. Ferree | Treating degenerative disc disease through transplantation of allograft disc and vertebral endplates |
US6723335B1 (en) | 2000-04-07 | 2004-04-20 | Jeffrey William Moehlenbruck | Methods and compositions for treating intervertebral disc degeneration |
JP2003531604A (en) | 2000-04-28 | 2003-10-28 | チルドレンズ メディカル センター コーポレーション | Isolation and use of mesenchymal stem cells |
AU2001270408A1 (en) | 2000-06-29 | 2002-01-08 | Mount Sinai Hospital | Intervertebral disc |
US9387094B2 (en) | 2000-07-19 | 2016-07-12 | Warsaw Orthopedic, Inc. | Osteoimplant and method of making same |
US6752831B2 (en) | 2000-12-08 | 2004-06-22 | Osteotech, Inc. | Biocompatible osteogenic band for repair of spinal disorders |
AU2002318159A1 (en) | 2001-06-29 | 2003-03-03 | The Regents Of The University Of California | Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs |
CN101696397B (en) | 2001-07-06 | 2015-07-08 | 阿斯特利亚斯生物治疗股份公司 | Mesenchymal cells and osteoblasts from human embryonic stem cell |
JP3728750B2 (en) | 2001-11-22 | 2005-12-21 | ニプロ株式会社 | Cultured skin and method for producing the same |
US20050158397A1 (en) | 2002-01-14 | 2005-07-21 | Michael Chopp | Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors |
US20050118714A1 (en) | 2002-02-19 | 2005-06-02 | Chul-Won Ha | Isolation and culture-expansion methods of mesenchymal stem/progenitor cells from umbilical cord blood and differentation method of umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues |
US6890354B2 (en) | 2002-03-08 | 2005-05-10 | Musculoskeletal Transplant Foundation | Bone-tendon-bone assembly with allograft bone block and method for inserting same |
US6730124B2 (en) | 2002-03-08 | 2004-05-04 | Musculoskeletal Transplant Foundation | Bone-tendon-bone assembly with cancellous allograft bone block |
US7931687B2 (en) | 2002-05-13 | 2011-04-26 | Articular Engineering, Llc | Tissue engineered osteochondral implant |
JPWO2004018658A1 (en) | 2002-08-23 | 2005-12-08 | 宣男 櫻川 | Human bone stem cells |
DE602004028803D1 (en) | 2003-02-11 | 2010-10-07 | John E Davies | PRECURSOR CELLS FROM THE WHARTON SULCE OF HUMAN NECK LOCKS |
US20040197375A1 (en) | 2003-04-02 | 2004-10-07 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
ES2597837T3 (en) | 2003-06-27 | 2017-01-23 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of manufacturing and using them |
US20050118147A1 (en) | 2003-11-17 | 2005-06-02 | Il-Hoan Oh | Method of using mesenchymal stromal cells to increase engraftment |
RU2252252C1 (en) | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Method for isolation of mesenchymal stem cells |
CA2971062C (en) | 2004-08-16 | 2019-02-26 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
JP5340599B2 (en) | 2004-12-23 | 2013-11-13 | エシコン・インコーポレイテッド | Umbilical tissue-derived postpartum cells and methods for producing and using the same |
US20060182724A1 (en) | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
WO2007027157A1 (en) | 2005-09-02 | 2007-03-08 | Agency For Science, Technology And Research | Method of deriving progenitor cell line |
US9029146B2 (en) | 2005-09-02 | 2015-05-12 | Agency For Science, Technology And Research | Mesenchymal stem cell conditioned medium |
US8187639B2 (en) | 2005-09-27 | 2012-05-29 | Tissue Tech, Inc. | Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment |
CA2949643C (en) | 2005-09-27 | 2018-05-15 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
CN103555655B (en) | 2005-10-21 | 2018-02-27 | 细胞研究私人有限公司 | The application of ancestral cells and its cell of differentiation is separated and cultivated from umbilical cord amniotic membrane |
US20090170059A1 (en) | 2005-11-14 | 2009-07-02 | Hans Klingemann | Methods for Preparing Cord Matrix Stem Cells (CMSC) for Long Term Storage and for Preparing a Segment of umbilical cord for cryopreservation |
US20070128722A1 (en) | 2005-12-05 | 2007-06-07 | Industrial Technology Research Institute | Human mesenchymal stem cells and culturing methods thereof |
AU2006329195B2 (en) | 2005-12-22 | 2012-09-20 | John E. Davies | Viable cells from frozen umbilical cord tissue |
GB0600972D0 (en) | 2006-01-18 | 2006-03-01 | Univ Leeds | Enrichment of cells |
CN101421393B (en) | 2006-02-14 | 2013-08-14 | 塞勒兰特治疗公司 | Methods and compositions for enhancing engraftment of hematopoietic stem cells |
EP1989294A4 (en) | 2006-03-01 | 2009-09-23 | Regenerative Medicine Inst | Compostions and populations of cells obtained from the umbilical cord and methods of producing the same |
ES2453373T3 (en) | 2006-04-14 | 2014-04-07 | Wako Pure Chemical Industries, Ltd. | Procedure for introducing a plurality of solutions into a microfluidic channel |
US8734827B2 (en) | 2006-04-28 | 2014-05-27 | University Of Hong Kong | Bioengineered intervertebral discs and methods for their preparation |
CA2871219C (en) | 2006-05-05 | 2020-06-30 | John E. Davies | Immune privileged and modulatory progenitor cells |
US20080166804A1 (en) | 2006-07-14 | 2008-07-10 | Shamblott Michael J | Compostions and methods for growing human embryonic stem cells |
US20080118477A1 (en) | 2006-11-09 | 2008-05-22 | Rush University Medical Center | Umbilical cord mesenchymal stem cells support cord blood hematopoiesis |
AU2007332799A1 (en) | 2006-12-07 | 2008-06-19 | Teva Pharmaceutical Industries Ltd. | Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue |
US20120100607A1 (en) | 2007-07-12 | 2012-04-26 | Christopher Duntsch | Compositions of adult disc stem cells and methods for the treatment of degenerative disc disease |
EP2679672B1 (en) | 2007-07-12 | 2016-11-30 | Discgenics | Human disc tissue |
US20090068153A1 (en) | 2007-09-06 | 2009-03-12 | Vitelli Francesca P | Cell composition for tissue regeneration |
FR2927633B1 (en) | 2008-02-19 | 2012-07-13 | Commissariat Energie Atomique | SYSTEM AND METHOD FOR THE CLONAL CULTURE OF EPITHELIAL CELLS AND THEIR USE. |
US20090232781A1 (en) | 2008-03-13 | 2009-09-17 | Yu-Show Fu | Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells |
US20090232782A1 (en) | 2008-03-14 | 2009-09-17 | Yu-Show Fu | Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells |
US20120219531A1 (en) | 2008-03-17 | 2012-08-30 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
US20110143433A1 (en) | 2008-03-17 | 2011-06-16 | Agency For Science, Technology And Research | Microcarriers for Stem Cell Culture |
CA2741426C (en) | 2008-10-31 | 2020-04-21 | Meredith Hans | Method and device for activating stem cells |
WO2011071476A2 (en) | 2008-11-14 | 2011-06-16 | Life Technologies Corporation | Compositions and methods for engineering cells |
EP2367932B1 (en) | 2008-11-19 | 2019-06-12 | Celularity, Inc. | Amnion derived adherent cells |
US20100274355A1 (en) | 2009-01-21 | 2010-10-28 | Mcguire David A | Bone-tendon-bone assembly with cancellous allograft bone block having cortical end portion |
US9511093B2 (en) | 2009-03-23 | 2016-12-06 | The Texas A & M University System | Compositions of mesenchymal stem cells to regenerate bone |
US9044335B2 (en) | 2009-05-05 | 2015-06-02 | Cornell University | Composite tissue-engineered intervertebral disc with self-assembled annular alignment |
US20120141595A1 (en) | 2009-08-25 | 2012-06-07 | Tissuetech, Inc. | Umbilical cord amniotic membrane products |
WO2011063128A1 (en) | 2009-11-18 | 2011-05-26 | Affinergy, Inc. | Implantable bone graft materials |
US8278101B2 (en) | 2009-12-07 | 2012-10-02 | Synthecon, Inc. | Stem cell bioprocessing and cell expansion |
EP2524034A1 (en) | 2010-01-14 | 2012-11-21 | Organogenesis, Inc. | Bioengineered tissue constructs and methods for producing and using thereof |
US20150010506A1 (en) | 2010-02-18 | 2015-01-08 | Osiris Therapeutics, Inc. | Therapeutic placental compositions, methods of making and methods of use |
US20110262486A1 (en) | 2010-04-22 | 2011-10-27 | Taipei Medical University | Bone implant and manufacturing method thereof |
CA2826377C (en) | 2011-02-14 | 2020-12-15 | Mimedx Group Inc. | Laminated tissue grafts composed of wharton's jelly and methods of making and using the same |
US9526770B2 (en) | 2011-04-28 | 2016-12-27 | Tissuetech, Inc. | Methods of modulating bone remodeling |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
US9682044B2 (en) | 2011-06-10 | 2017-06-20 | Tissuetech, Inc. | Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof |
RU2455353C1 (en) | 2011-06-14 | 2012-07-10 | Общество с ограниченной ответственностью "Медицинские технологии" | Cell product for auto- and allografting prepared of human umbilical cord, and method for preparing thereof |
RU2455357C1 (en) | 2011-06-14 | 2012-07-10 | Общество с ограниченной ответственностью "Медицинские технологии" | Cell product for auto- and allografting prepared of human umbilical cord, and method for preparing thereof |
US9931423B2 (en) | 2011-08-26 | 2018-04-03 | Tissuetech, Inc. | Methods of sterilizing fetal support tissues |
EP2768542A4 (en) | 2011-10-21 | 2015-08-05 | Univ Maryland | Bone pastes comprising biofunctionalized calcium phosphate cements with enhanced cell functions for bone repair |
GB201118586D0 (en) | 2011-10-27 | 2011-12-07 | Turzi Antoine | New A-PRP medical device, manufacturing machine and process |
US9315776B2 (en) | 2011-11-09 | 2016-04-19 | National University Of Singapore | Wharton's jelly mesenchymal stem cells and uses thereof |
US20130136722A1 (en) | 2011-11-11 | 2013-05-30 | The Board Of Trustees Of The University Of Illinois | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts |
CA2857640C (en) | 2011-12-02 | 2021-11-16 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
US9803176B2 (en) | 2011-12-30 | 2017-10-31 | Amit Patel | Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses |
WO2013109969A1 (en) | 2012-01-20 | 2013-07-25 | University Of Miami | Co-cultured mesenchymal stem cells and myocytes |
US8940294B2 (en) | 2012-03-02 | 2015-01-27 | Tissuetech, Inc. | Methods of isolating and culturing stem cells |
JP2015528001A (en) | 2012-07-11 | 2015-09-24 | ティッシュテック,インク. | Composition comprising HC-HA / PTX3 complex and method of use thereof |
US9655994B2 (en) | 2012-07-25 | 2017-05-23 | William F. McKay | Delivery systems |
US9114190B2 (en) | 2013-02-08 | 2015-08-25 | Laser Spine Institute, Llc | Regeneration of spinal discs |
US9517128B2 (en) | 2013-03-08 | 2016-12-13 | The Trustees Of Princeton University | Multi-functional hybrid devices/structures using 3D printing |
US9283013B2 (en) | 2013-03-14 | 2016-03-15 | Warsaw Orthopedic, Inc. | Filling systems for bone delivery devices |
US9381274B2 (en) * | 2013-03-14 | 2016-07-05 | Prosidyan, Inc. | Bone graft implants containing allograft |
WO2014151939A1 (en) | 2013-03-15 | 2014-09-25 | Allosource | Perforated osteochondral allograft compositions |
AU2014329513A1 (en) | 2013-10-03 | 2016-04-28 | Celularity Inc. | Therapy with cells from human placenta and hematopoietic cells |
EP3140417B1 (en) | 2014-05-09 | 2021-04-21 | Reelabs Private Limited | Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders |
US9867641B2 (en) | 2014-05-15 | 2018-01-16 | Brahm Holdings, Llc | Spinal graft |
EP3149157A4 (en) | 2014-05-24 | 2018-06-13 | Neelamkrishnan Venkataramanaa | A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord |
WO2016004212A1 (en) | 2014-07-01 | 2016-01-07 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating wounds and methods for making and using them |
KR101633019B1 (en) | 2014-07-25 | 2016-06-23 | 주식회사 비비에이치씨 | Method for Preparing Induced Pluripotency Stem Cell from Mesenchymal Stem Cell and Production thereof |
SG11201700753YA (en) | 2014-07-29 | 2017-02-27 | Ingeneron Inc | Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof |
WO2016033385A1 (en) | 2014-08-28 | 2016-03-03 | Mimedx Group, Inc. | Collagen reinforced tissue grafts |
WO2016070057A1 (en) | 2014-10-30 | 2016-05-06 | Stembiosys, Inc. | Methods for maintaining and expanding mesenchymal stem cells on extracellular matrix coated microcarriers |
WO2016073989A2 (en) | 2014-11-07 | 2016-05-12 | The Trustees Of Columbia University In The City Of New York | Osteochondroreticular stem cells for bone and cartilage regeneration |
WO2016187555A1 (en) | 2015-05-20 | 2016-11-24 | Tissuetech, Inc. | Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
CA2986702C (en) | 2015-05-21 | 2023-04-04 | David Wang | Modified demineralized cortical bone fibers |
US10383731B2 (en) | 2016-02-24 | 2019-08-20 | Warsaw Orthopedic, Inc. | Spinal implant system and method |
US20170296588A1 (en) | 2016-04-19 | 2017-10-19 | AngioStem, Inc. | Mesenchymal stem cells derived from placental sources |
-
2018
- 2018-12-05 US US16/210,464 patent/US11285177B2/en active Active
-
2022
- 2022-02-16 US US17/672,983 patent/US20220168356A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067480A1 (en) * | 2002-10-04 | 2004-04-08 | Organ Recovery Systems, Inc. | Method for treatment of cellular materials with sugars prior to preservation |
US20080014179A1 (en) * | 2006-07-11 | 2008-01-17 | Ferree Bret A | Tissue transplantation compositions and methods |
US9655929B2 (en) * | 2014-07-17 | 2017-05-23 | Vivex Biomedical, Inc. | Spinal disc regenerative composition and method of manufacture and use |
US11285177B2 (en) * | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
Non-Patent Citations (3)
Title |
---|
Capossela et al. (European Cells and Materials 2014;27:251-263) (Year: 2014) * |
Tan et al. (Materials 2010;3:1746-1767) (Year: 2010) * |
Valeri et al. (Transfusion 1996;36:303-308). (Year: 1996) * |
Also Published As
Publication number | Publication date |
---|---|
US20190201451A1 (en) | 2019-07-04 |
US11285177B2 (en) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11357889B2 (en) | Native soft tissue matrix for therapeutic applications | |
US20220168356A1 (en) | Allografts containing viable cells and methods therof | |
US8313743B2 (en) | Use of adipose tissue-derived stromal cells in spinal fusion | |
US20090054983A1 (en) | Bioresorbable bone implant | |
Helm et al. | Bone graft substitutes for the promotion of spinal arthrodesis | |
Parizi et al. | Effectiveness of synthetic hydroxyapatite versus Persian Gulf coral in an animal model of long bone defect reconstruction | |
US9889233B2 (en) | Method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair | |
Smrke et al. | Treatment of bone defects—allogenic platelet gel and autologous bone technique | |
Xie et al. | The performance of a bone-derived scaffold material in the repair of critical bone defects in a rhesus monkey model | |
Kanczler et al. | Bone tissue engineering and bone regeneration | |
Rapp et al. | Repairing critical-sized rat calvarial defects with progenitor cell-seeded acellular periosteum: a novel biomimetic scaffold | |
Kim et al. | Effect of acellular dermal matrix as a delivery carrier of adipose‐derived mesenchymal stem cells on bone regeneration | |
Tshamala et al. | Osteoinductive properties of the bone marrow Myth or reality | |
Wang et al. | Repair of orbital bone defects in canines using grafts of enriched autologous bone marrow stromal cells | |
Hassibi et al. | Allogenic bone graft enriched by periosteal stem cell and growth factors for osteogenesis in critical size bone defect in rabbit model: histopathological and radiological evaluation | |
WO2016160717A1 (en) | Endochondral tissue engineering for vascularized bone regeneration | |
US10183095B2 (en) | Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate | |
US20200093958A1 (en) | Allografts containing amniotic fluid and methods therof | |
US9693873B1 (en) | In vitro production of bone-like material | |
RU2269961C2 (en) | Method for autotransplanting immobilized medullary stromal stem cells | |
US20190314163A1 (en) | Spinal implant and related methods | |
Bae et al. | Does autologous bone marrow aspirate enhance graft effectiveness for spinal fusion? | |
Cordonnier et al. | Healing of long-bone defects in sheep metatarsals using bioceramics and mesenchymal stem cells | |
Sinclair | The development of a mesenchymal stem cell based bone graft system | |
US20150224147A1 (en) | Placental Membrane Preparation and Methods of Making and Using Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLOBUS MEDICAL, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAUL, DAVID C.;BHAT, ARCHANA;SEIBER, BREANNA;SIGNING DATES FROM 20180103 TO 20180110;REEL/FRAME:059025/0023 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |